Washington

Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society

SEATTLE, Sept. 5, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with…
Continue Reading »